Peptide Therapy for Long COVID

Long COVID was not recognized as a distinct clinical entity until mid 2020, when patients who recovered from acute SARS-CoV-2 infection reported persistent symptoms months later. Estimates suggest 10 to 30 percent of COVID patients develop some form of long hauler syndrome. The condition includes fatigue, cognitive impairment, exercise intolerance, post exertional malaise, dysautonomia, and chronic inflammation. Mainstream medicine has struggled to treat long COVID. There is no FDA approved therapy specifically for it. Management has been supportive, addressing individual symptoms with existing medications. This left a gap that integrative and regenerative medicine practitioners began filling with experimental approaches, including peptide therapy. Peptides became attractive for long COVID because several compounds target the specific pathophysiology researchers identified in long haulers: mitochondrial dysfunction, persistent immune activation, gut barrier disruption, and neuroinflammation. These are exactly the pathways that peptides like MOTS-c, thymosin alpha-1, BPC-157, and Selank are designed to modulate. By 2021, peptide protocols for long COVID were appearing in integrative medicine clinics and online patient communities. The approach was driven by mechanistic reasoning rather than large clinical trials, since those trials had not been conducted yet. Small case series and patient reported outcomes provided the initial evidence base.

Long COVID appears to involve several overlapping mechanisms, and different peptides target different ones. Thymosin alpha-1 (Ta1) is a 28 amino acid peptide naturally produced by the thymus gland. It modulates immune function by enhancing T cell maturation, promoting dendritic cell activity, and balancing pro and anti inflammatory cytokines. In long COVID, where immune dysregulation and persistent low grade inflammation are common, Ta1 helps restore normal immune calibration. It is FDA approved as thymalfasin (Zadaxin) for hepatitis B in several countries and used off label for immune support in the US. MOTS-c is a mitochondrial derived peptide that regulates metabolic homeostasis. Long COVID research has identified mitochondrial dysfunction as a major driver of fatigue and exercise intolerance in long haulers. MOTS-c activates AMPK pathways, improves insulin sensitivity, and enhances cellular energy production. It addresses the metabolic component of long COVID that many other treatments miss. BPC-157 is a gastric pentadecapeptide with broad regenerative properties. It promotes angiogenesis (new blood vessel formation), modulates nitric oxide pathways, and supports gut barrier integrity. Many long COVID patients have gastrointestinal symptoms and increased intestinal permeability. BPC-157 addresses gut repair while also supporting tissue healing systemically. Selank is a synthetic tuftsin analog with nootropic and anxiolytic properties. It modulates GABA and serotonin signaling, reduces neuroinflammation, and has been studied for cognitive impairment in Russia since the early 2000s. For long COVID brain fog, Selank targets the neuroinflammatory component that causes cognitive dysfunction.

Each peptide addresses specific long COVID symptom clusters. Thymosin alpha-1 reduces the chronic immune activation that drives fatigue and malaise. Users report improved energy levels, fewer infections, and reduced inflammatory markers like CRP and IL-6. Some practitioners use it as a first line intervention to calm the immune system before adding other peptides. MOTS-c improves the cellular energy deficit that causes exercise intolerance and post exertional malaise. Users report increased exercise capacity, better recovery from physical activity, and more stable energy throughout the day. It is particularly useful for long COVID patients whose primary complaint is crushing fatigue. BPC-157 addresses gut symptoms (bloating, pain, irregular bowel movements) and supports systemic tissue repair. Long COVID patients with joint pain, tendon issues, or gut dysfunction often respond to BPC-157 within 4 to 8 weeks. It also has neuroprotective properties that may complement Selank for brain fog. Selank targets cognitive symptoms directly. Users report improved mental clarity, reduced brain fog, better word recall, and decreased anxiety. The effect is more noticeable than the other peptides, some users feel improvement within days. When used together in a protocol, these peptides address multiple long COVID mechanisms simultaneously, which is important because the condition involves several overlapping pathways.

Long COVID patients who have tried peptide therapy report a gradual return to normal function rather than a dramatic cure. A user on r/covidlonghaulers shared: “I was 14 months into long COVID with fatigue, brain fog, and PEM that knocked me out for days after any exertion. My doctor put me on thymosin alpha-1 and MOTS-c. After 6 weeks on Ta1, my resting heart rate dropped 8 bpm and I stopped catching every cold my kids brought home. MOTS-c took longer, about 2 months, but I started being able to walk 30 minutes without crashing the next day. Not cured, but functional again.“ Another user on r/Peptides described: “BPC-157 fixed my gut issues within 3 weeks, the bloating and pain that had been constant since COVID just stopped. Added Selank for the brain fog, 300 mcg intranasal twice daily. By week 2 I could read a full article without re-reading paragraphs. The fog lifted gradually, not all at once. I still have bad days but they are less frequent and less severe.“ The typical timeline varies by symptom. Brain fog improvements with Selank can begin within days to weeks. Immune modulation with thymosin alpha-1 shows effects in 4 to 8 weeks. Mitochondrial repair with MOTS-c takes 6 to 12 weeks. Gut healing with BPC-157 occurs over 4 to 8 weeks.

• Reduced fatigue and improved energy stamina
• Clearer thinking, less brain fog, better word recall
• Decreased post exertional malaise, ability to exercise without crashing
• Improved gut function, less bloating and pain
• Reduced chronic inflammation markers
• Better immune resilience, fewer secondary infections
• Improved sleep quality
• Reduced anxiety and mood instability
• Better exercise tolerance and physical recovery
• Gradual return to pre COVID activity levels

The four peptides mentioned above are often used in combination because long COVID involves multiple systems. A common protocol starts with thymosin alpha-1 to modulate immune function, adds MOTS-c for mitochondrial support, includes BPC-157 for gut repair, and adds Selank for cognitive symptoms. KPV is a tripeptide derived from alpha MSH with anti inflammatory properties. It is used alongside BPC-157 for gut inflammation and can be taken orally. It is a lower cost addition that supports the anti inflammatory component. SS-31 (elamipretide) targets mitochondrial membrane integrity more directly than MOTS-c. Some practitioners use SS-31 and MOTS-c together for patients with severe mitochondrial dysfunction. SS-31 protects the mitochondrial membrane while MOTS-c improves mitochondrial gene expression. Epitalon is a peptide that supports telomerase activity and pineal gland function. It is used by some long COVID patients for sleep regulation, since insomnia and circadian disruption are common in long haulers. It pairs with the other peptides without significant interaction concerns.